On November 4, local time, the Swiss company Idorsia announced that Dali Raison has been certified as a “breakthrough therapy” by the US Food and Drug Administration to treat insomnia disorders in children and adolescents aged 10 to under 18. Currently, there is no drug treatment plan approved by the FDA in the field of childhood insomnia. Last year, Dali Leisheng was approved for marketing in China to treat adult insomnia patients. Xiansheng Pharmaceutical currently has exclusive rights to develop and commercialize Dali Raison in the Greater China region.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.